Short-Term Effects of Escalating Doses of Cholecalciferol on FGF23 and 24,25(OH)2 Vitamin D Levels: A Preliminary Investigation
Nutrients · 2024
DOI: 10.3390/nu16213600 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Jessica Pepe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy. Hauptthemen laut MEDLINE: Fibroblast Growth Factor-23, Cholecalciferol, Fibroblast Growth Factors, Vitamin D. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was partly funded by an unrestricted grant from Nycomed pharmaceutical company., an unrestricted grant from Nycomed pharmaceutical company.
Abstract (Originalsprache)
Background
There are few and controversial results on 24,25(OH)2D and FGF23 acute changes following supplementation with cholecalciferol.
Methods
Twenty-seven subjects with 25(OH)D < 30 ng/mL were randomized into three groups to receive a single oral dose of 25,000 I.U. or 600,000 I.U. of cholecalciferol or placebo, respectively. We measured 25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and FGF23 levels at baseline and after 72 h. The 1,25(OH)2D/25(OH)D, 1,25(OH)2D/24,25(OH)2D, and 24,25(OH)2D/25(OH)D ratios were also calculated.
Results
There was an increase in 25(OH)D and 1,25 (OH)2D following both doses of cholecalciferol. In the group administered 600,000 I.U., there was a significant increase in the delta changes in 25(OH)D and 1,25(OH)2D compared to the placebo and in the delta 24,25(OH)D2 compared to the placebo and 25,000 I.U. groups (all p < 0.05). A decrease in both the 1,25(OH)2D/25(OH)D and 1,25(OH)2D/24,25(OH)2D ratio (all p < 0.05) was observed in the 600,000 I.U. group. FGF23 values significantly increased only in the group administered 600,000 I.U.
Conclusions
25(OH)D and 1,25(OH)D levels significantly increased following 600,000 IU cholecalciferol administration compared to 25,000 I.U. and placebo. Following the massive administration of cholecalciferol, the CYP24A1 enzyme is actively involved in catabolism, thus, avoiding toxic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences (SCIAC), "Sapienza" University of Rome, 00161 Rome, Italy.
- Istituto Superiore di Sanità, 00161 Rome, Italy.
- Unit of Endocrinology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, 71013 Foggia, Italy.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Luciano Colangelo, Viviana De Martino, Carla Ferrara, Salvatore Minisola, Cristiana Cipriani
Förderung
- This study was partly funded by an unrestricted grant from Nycomed pharmaceutical company.
- an unrestricted grant from Nycomed pharmaceutical company
Zitieren
APA
Pepe, J., Colangelo, L., Pilotto, R., De Martino, V., Ferrara, C., Scillitani, A., Cilli, M., Minisola, S., Singh, R., & Cipriani, C. (2024). Short-Term Effects of Escalating Doses of Cholecalciferol on FGF23 and 24,25(OH)2 Vitamin D Levels: A Preliminary Investigation. Nutrients. https://doi.org/10.3390/nu16213600
Vancouver
Pepe J, Colangelo L, Pilotto R, De Martino V, Ferrara C, Scillitani A, et al. Short-Term Effects of Escalating Doses of Cholecalciferol on FGF23 and 24,25(OH)2 Vitamin D Levels: A Preliminary Investigation. Nutrients. 2024. doi:10.3390/nu16213600
BibTeX
@article{Pepe2024,
author = {Pepe, Jessica and Colangelo, Luciano and Pilotto, Roberta and De Martino, Viviana and Ferrara, Carla and Scillitani, Alfredo and Cilli, Mirella and Minisola, Salvatore and Singh, Ravinder and Cipriani, Cristiana},
title = {Short-Term Effects of Escalating Doses of Cholecalciferol on FGF23 and 24,25(OH)2 Vitamin D Levels: A Preliminary Investigation},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16213600}
}
EUVIMED